• 09 Dec 19

ReNeuron in active on-going talks for further potential out-licence deals

ReNeuron in active on-going talks for further potential out-licence deals

ReNeuron Group plc | RNUGF | 0 0 0%

    • 75 views

 

ReNeuron Group PLC's (LON:RENE) Michael Hunt caught up with Proactive London's Andrew Scott soon after the release of its interim results to September 2019.

The biotech firm says it's in ongoing discussions with “commercial third parties” interested in out-licence deals across all its programmes.

Enjoying this article?

Get a £25 credit by sharing with your friends and colleagues via our Refer a Friend page. Each new subscriber gets a 10% discount and you get a free month off your bill every time.


Don't worry, if you're a Lite-Access/Free user we save all your credits for the day you decide to fully subscribe.


 

ReNeuron (LON:RENE) Presenting at the Proactive One2One Virtual Forum 25th February 2021

Companies: ReNeuron Group plc

Executive Interview - ReNeuron

Companies: ReNeuron Group plc

ReNeuron – Edison Open House interview

Companies: ReNeuron Group plc

Executive Interview - ReNeuron

Companies: ReNeuron Group plc

ReNeuron Group completes first dosing of patients in study for new degenerative eye disease therapy

Companies: ReNeuron Group plc

Executive Interview - ReNeuron

Companies: ReNeuron Group plc

© Research Tree 2025

  • Apple Store
  • Play Store

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top